Is Zimmer Biomet Holdings Inc (ZBH) overvalued? · P/E 23, rev $7.68B
Zimmer Biomet Holdings Inc (ZBH) is a medical devices company listed on NYSE.
This page asks whether Zimmer Biomet Holdings Inc (ZBH) looks expensive on cached numbers — not a short thesis.
Latest reported ZBH revenue for 2024-12-31 was $7.68B. Net income was $905.3M. Revenue was up 3.8% from 2023-12-31 to 2024-12-31. ZBH currently screens at market cap $17.13B and trailing P/E 22.9.
ZBH currently screens at market cap $17.13B and trailing P/E 22.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ZBH 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ZBH stock page for the full model, not this heading.
Not investment advice.